Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

摘要

Correction to: British Journal of Cancer (2016) 114 , 723–730; doi: 10.1038/bjc.2016.41 ; published online 22 March 2016 Updated online 26 May 2016: This article was originally published under a standard BJC licence, but has now been made available under a CC BY 4.0 licence. The PDF and HTML versions of the paper have been modified accordingly.